Altrazeal Life Sciences Inc.

Altrazeal Life Sciences Inc., doing business as Uluru, is a for-profit medical equipment manufacturer and drug delivery solutions company headquartered in Addison, Texas, and registered in SAM.gov since December 2008. The company specializes in developing advanced medical technologies for trauma treatment and wound care applications, with a particular focus on innovative solutions designed for military and austere care settings. Altrazeal has established itself as a reliable federal contractor and grant recipient, demonstrating sustained expertise in research and development initiatives that address critical healthcare challenges in military and low-resource environments.

Through federal contract awards, Altrazeal Life Sciences has received multiple Small Business Innovation Research (SBIR) contracts totaling approximately $4.2 million from both the Defense Health Agency and the U.S. Army Medical Command. The company's contract work centers on two primary research initiatives: developing an innovative and adaptive drug delivery system for enhanced neuroprotection and repair in traumatic brain injuries resulting from penetrating trauma or open skull fractures in low-resource environments, and developing an ideal first-use agent to prevent sepsis in trauma wounds during care under fire. Specifically, the company received a Phase I SBIR contract from the Army Medical Command on April 26, 2021 ($167,448.80), followed by a Phase II SBIR contract from the Army Medical Command on September 6, 2022 ($1,155,968.00), both focused on sepsis prevention in trauma wounds. The company subsequently received a Phase I SBIR contract from the Defense Health Agency on October 7, 2024 ($249,999.96) for the traumatic brain injury drug delivery system, which was followed by a Phase II SBIR contract from the Defense Health Agency on February 7, 2025 ($1,300,000.00) for the sepsis prevention initiative, and another Phase II SBIR contract from the Defense Health Agency on September 5, 2025 ($1,299,999.92) for the traumatic brain injury application. All contracts are designated as total small business set-asides and involve firm fixed-price arrangements with work performed at the contractor's facility in Addison, Texas.

Through federal grant awards, Altrazeal Life Sciences serves as both a prime grantee and sub-awardee on Defense Health Agency-funded initiatives focused on advanced wound care and healing technologies. As the prime grantee, the company received a project grant from the Defense Health Agency on September 1, 2021 for an innovative wound management solution designed to reduce dressing changes and burden of care in the treatment of pressure injuries, with an ultimate completion date of August 31, 2026 and a recent amendment dated August 15, 2025 that extended the period of performance and adjusted principal investigator effort allocation. Additionally, Altrazeal Life Sciences serves as a sub-awardee under a Defense Health Agency grant administered by The Henry M. Jackson Foundation for the Advancement of Military Medicine, with a sub-award date of May 1, 2023, focused on evaluating components and bioactive agents to improve chronic wound healing. This sub-award work specifically evaluates the Transforming Powder Dressing (TPD), an FDA-registered product developed and proprietary to Altrazeal Life Sciences, which serves as a carrier platform for biologically active agents including analgesics, plasma volume expanders, hemostats, regenerative agents, and antimicrobials with controlled release kinetics designed for wound treatment across all echelons of military care and throughout the continuum of care.